Posts Tagged ‘Bloomberg News’:


formats

Drug Approvals Up for 2011

Published on January 20, 2012 by in FDA, General Drug News & Safety

Posted January 9, 2012 by The Scientist The FDA approved 30 drugs last year, the highest number in the last 7 years. The US Food and Drug Administration approved 30 drugs in 2011, compared with 21 in 2010, according to an analysis by Bloomberg News. That number is the highest since 36 drugs were approved in 2004. Some of the headline drugs to get the green light include Yervoy, a drug that primes the immune system to attack melanoma; Xarelto, which reduces clotting for patients with irregular heartbeats; and Benlysta, the first lupus drug approved in 50 years. The FDA toughened its data requirements in 2007, after critics faulted its response to claims of heart

[Continue Reading]

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

Avandia Injury Lawsuit Settlement Negotiations Continue

Published on November 21, 2011 by in Avandia, GSK

Posted November 10, 2011 by About Lawsuits The federal judge presiding over all Avandia lawsuits is pushing further settlement negotiations between GlaxoSmithKline and plaintiffs in all remaining injury cases, indicating that cases will be set for trial if the vast majority of the lawsuits are not settled within the next three months. U.S. District Judge Cynthia Rufe has appointed a mediator in the federal Avandia MDL, multidistrict litigation, to over see the settlement negotiations, with a 75 day deadline for 85% of all pending lawsuits to be settled. According to a report by Bloomberg News, the Judge has suggested that cases will be fast-tracked for trial if the deadline is not met, designating some of

[Continue Reading]

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

Settlement of Avandia Lawsuits Reached in About 10,000 More Cases

Published on January 30, 2011 by in Avandia, GSK

Posted July 13, 2010 by AboutLawsuits.com GlaxoSmithKline has reportedly agreed to pay $460 million to settle Avandia lawsuits filed by about 10,000 more people. The agreement comes as two FDA advisory committees have begun meeting to debate whether the controversial diabetes drug should be recalled from the market. The Avandia settlement was leaked to Bloomberg News the same day as the committees of independent advisors to the FDA were hearing evidence about the heart risks of Avandia that were the subject of the injury suits. The settlement would resolve the majority of the outstanding Avandia lawsuits that have been filed against GlaxoSmithKline alleging that they failed to warn about the increased risk of heart attacks

[Continue Reading]

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

Glaxo Paxil Birth Defects Settlements Total $1 Billion

Published on November 24, 2010 by in Birth Defects, GSK, Paxil

Posted July 22, 2010 on Parker Waichman Alonso GlaxoSmithKline (GSK) has agreed to pay in excess of $1 billion to settle hundreds of lawsuits over claims of birth defects linked to Paxil, said Fierce Pharma. The $1 billion is from the drug maker’s $2.4 billion legal expense budget and will pay about $1.2 million to each of families whose children were born with birth defects following their mothers’ use of Paxil during pregnancy, said Fierce Pharma. Over 800 Paxil birth defect cases will be resolved with this massive settlement; over 100 additional cases remain pending according to Bloomberg News, wrote Fierce Pharma. Claire Brough, a spokeswoman for GlaxoSmithKline did confirm to Reuters that additional cases

[Continue Reading]

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

Glaxo Memo Suggested Burying Paxil Birth Defect Evidence

Published on November 22, 2010 by in Birth Defects, Carey & Danis, GSK, Paxil

Posted February 15, 2010 on Carey & Danis Worried that animal studies would link the antidepressant Paxil with birth defects, an executive with the drug’s maker, GlaxoSmithKline, suggested burying the evidence, Bloomberg News reports. Written in 1997, the memo urged scientists to withhold information about the birth defect risks the drug posed to pregnant women. A company scientist had noted that rat studies of the Paxil compound in 1980 showed that young rats often died after receiving low doses of the drug. Those deaths could suggest birth defects. A year after the memo was written, in 1998, a Glaxo internal review found an alarmingly high number of Paxil birth defect reports. However, the information was

[Continue Reading]

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments